Feed MRVI
MR

Maravai LifeSciences Holdings, Inc. MRVI NASDAQ · Healthcare · United States

$7.28 -1.62% -$0.12

Summary

20 / 100 · Bulios Score

What speaks for it

  • Analysts expect revenue to grow by 15% this fiscal year.
  • The price moves less than the market (beta 0.63).

What to watch

  • Revenue fell by 41% a year over the last 3 years.
  • The company made a loss over the last 12 months.
  • The share price is above the Bulios Fair Price.
  • It passes only 3 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $7.28

By our assumptions the business is worth less than its shares cost today.

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue fell by 8.1% a year over 5 years. Over the last 3 years it fell by 41% a year. For the next fiscal year analysts expect revenue to grow by 15%.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of $65.7M.

Profitability in detail

Is it financially healthy?

Debt is a burden

Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $8 is 9.9% above today's price. 57% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Shipping and Handling brings in 100% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy